SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 1898-1904. Prepublished online as a Blood First Edition Paper on November 12, 2004; DOI 10.1182/blood-2004-07-2975. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-07-2975v1 105/5/1898    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Straathof, K. C. M. Articles by Heslop, H. E. Search for Related Content PubMed PubMed Citation Articles by Straathof, K. C. M. Articles by Heslop, H. E. Related Collections Immunobiology Neoplasia Immunotherapy Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes Karin C. M. Straathof, Catherine M. Bollard, Uday Popat, M. Helen Huls, Teresita Lopez, M. Craig Morriss, Mary V. Gresik, Adrian P. Gee, Heidi V. Russell, Malcolm K. Brenner, Cliona M. Rooney, and Helen E. Heslop From the Center for Cell and Gene Therapy, Departments of Pediatrics, Radiology, Pathology, and Medicine, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX; The Methodist Hospital, Houston, TX; and Texas Children's Hospital, Houston TX. Conventional treatment for nasopharyngeal carcinoma (NPC) frequently fails and is accompanied by severe long-term side effects. Since virtually all undifferentiated NPCs are associated with Epstein-Barr virus (EBV), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated viral antigens. We now demonstrate that EBV-specific cytotoxic T-cell (CTL) lines can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation. A total of 10 patients diagnosed with advanced NPC were treated with autologous CTLs. All patients tolerated the CTLs, although one developed increased swelling at the site of pre-existing disease. At 19 to 27 months after infusion, 4 patients treated in remission from locally advanced disease remain disease free. Of 6 patients with refractory disease prior to treatment, 2 had complete responses, and remain in remission over 11 to 23 months after treatment; 1 had a partial remission that persisted for 12 months; 1 has had stable disease for more than 14 months; and 2 had no response. These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: "T"-ing off on nasopharynx cancer Fred Wang Blood 2005 105: 1841-1842. [Full Text] [PDF] This article has been cited by other articles: K. R.N. Baumforth, A. Birgersdotter, G. M. Reynolds, W. Wei, G. Kapatai, J. R. Flavell, E. Kalk, K. Piper, S. Lee, L. Machado, et al. Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells Am. J. Pathol., July 1, 2008; 173(1): 195 - 204. [Abstract] [Full Text] [PDF] T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines J. Immunol., February 1, 2008; 180(3): 1643 - 1654. [Abstract] [Full Text] [PDF] M. E. Dudley Warrior, miscreant, suicide: making better killers Blood, October 15, 2007; 110(8): 2781 - 2782. [Full Text] [PDF] C. Quintarelli, J. F. Vera, B. Savoldo, G. M. P. Giordano Attianese, M. Pule, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes Blood, October 15, 2007; 110(8): 2793 - 2802. [Abstract] [Full Text] [PDF] H. Zhang, K. M. Snyder, M. M. Suhoski, M. V. Maus, V. Kapoor, C. H. June, and C. L. Mackall 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy J. Immunol., October 1, 2007; 179(7): 4910 - 4918. [Abstract] [Full Text] [PDF] S. Landmeier, B. Altvater, S. Pscherer, B. R. Eing, J. Kuehn, C. M. Rooney, H. Juergens, and C. Rossig Gene-Engineered Varicella-Zoster Virus Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function Cancer Res., September 1, 2007; 67(17): 8335 - 8343. [Abstract] [Full Text] [PDF] M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF] Y. Ito, A. Demachi-Okamura, R. Ohta, Y. Akatsuka, K. Nishida, K. Tsujimura, Y. Morishima, T. Takahashi, and K. Kuzushima Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells J. Gen. Virol., March 1, 2007; 88(3): 770 - 780. [Abstract] [Full Text] [PDF] B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y.-F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) Blood, November 1, 2006; 108(9): 2942 - 2949. [Abstract] [Full Text] [PDF] C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J. F. Seymour, M. Gandhi, et al. Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope J. Immunol., October 1, 2006; 177(7): 4897 - 4906. [Abstract] [Full Text] [PDF] C. W. Tsang, X. Lin, N. H. Gudgeon, G. S. Taylor, H. Jia, E. P. Hui, A. T. C. Chan, C. K. Lin, and A. B. Rickinson CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes. J. Virol., August 1, 2006; 80(16): 8263 - 8266. [Abstract] [Full Text] [PDF] J S Kalpoe, P B Douwes Dekker, J H J M van Krieken, R J Baatenburg de Jong, and A C M Kroes Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area J. Clin. Pathol., May 1, 2006; 59(5): 537 - 541. [Abstract] [Full Text] [PDF] P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al. Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes J. Clin. Oncol., December 10, 2005; 23(35): 8942 - 8949. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020